Clinical Trial Update: Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC [Phase 2]

View source ↗

Summary

Phase 2 trial updating nivolumab in combination with chemotherapy or with ipilimumab for advanced EGFR-mutant or ALK-rearranged non-small cell lung cancer has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nivolumab in combination with chemotherapy (nivolumab)
• Nivolumab in combination with ipilimumab (nivolumab + ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2020-10-19